{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:55Z","timestamp":1792788595661,"version":"4.5.0"},"reference-count":42,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2021YFC2501704"],"award-info":[{"award-number":["2021YFC2501704"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-C&T-B-007"],"award-info":[{"award-number":["2021-I2M-C&T-B-007"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-051"],"award-info":[{"award-number":["2021-I2M-1-051"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873668"],"award-info":[{"award-number":["81873668"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070908"],"award-info":[{"award-number":["82070908"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7202153"],"award-info":[{"award-number":["7202153"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Osteogenesis imperfecta (OI) is a rare, heterogeneous, genetic disorder characterized by bone fragility and recurrent fractures. Bisphosphonates (BPs) are the most commonly used medications for OI, but their efficacy has great variability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We investigated the relationship of pathogenic gene mutations and responses to zoledronic acid (ZOL) in a large cohort of children with OI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children with OI who received ZOL treatment were included and were followed up for at least 1 year. Bone mineral density (BMD) and serum levels of \u03b2-isomerized carboxy-telopeptide of type I collagen (\u03b2-CTX, bone resorption marker) were measured at baseline and during follow-up. Causative mutations of OI were identified using next-generation sequencing and Sanger sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>201 children with OI were included. They had initiated ZOL treatment at a median age of 5 years, with mutations identified in 11 genes. After 3 years of treatment, the increase in femoral neck BMD Z-score in patients with OI with autosomal dominant (AD) inheritance was greater than that in patients with autosomal recessive or X-linked inheritance (non-AD) (4.5\u2005\u00b1\u20052.9 vs 2.0\u2005\u00b1\u20051.0, P\u2005&amp;lt;\u2005.001). Collagen structural defects were negatively correlated with the increase in femoral neck BMD Z-score. Patients with collagen structural defects had higher incidence of new fractures (35.1% vs 18.4%, relative risk 0.52, P\u2005=\u2005.044) and less decline in \u03b2-CTX level than those with collagen quantitative reduction. Increase in lumbar spine BMD and change in height Z-score was not associated with the genotype of children with OI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with OI with non-AD inheritance or with pathogenic mutations leading to collagen structural defects may have relatively poor responses to ZOL treatment, which is possibly associated with their more severe phenotypes. New therapeutic agents are worth developing in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac366","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T13:12:03Z","timestamp":1655817123000},"page":"2571-2579","source":"Crossref","is-referenced-by-count":12,"title":["Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-0337","authenticated-orcid":false,"given":"Lei","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing, 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing, 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing, 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing, 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing, 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing, 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing, 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing, 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-3511","authenticated-orcid":false,"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology of National Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College , Beijing, 100730 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"issue":"4","key":"2022081816085345700_CIT0001","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","article-title":"Osteogenesis imperfecta: an update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"Eur J Endocrinol."},{"issue":"9902","key":"2022081816085345700_CIT0002","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet."},{"issue":"12","key":"2022081816085345700_CIT0003","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res."},{"key":"2022081816085345700_CIT0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2016.02.015","article-title":"Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate","volume":"87","author":"Lindahl","year":"2016","journal-title":"Bone."},{"issue":"9419","key":"2022081816085345700_CIT0005","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet."},{"issue":"5","key":"2022081816085345700_CIT0006","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2022081816085345700_CIT0007","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","article-title":"Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment","volume":"40","author":"Land","year":"2007","journal-title":"Bone."},{"issue":"6","key":"2022081816085345700_CIT0008","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00223-016-0110-1","article-title":"Osteogenesis imperfecta type VI in individuals from northern Canada","volume":"98","author":"Ward","year":"2016","journal-title":"Calcif Tissue Int."},{"issue":"10","key":"2022081816085345700_CIT0009","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s00198-017-4141-x","article-title":"Long-term follow-up in osteogenesis imperfecta type VI","volume":"28","author":"Trejo","year":"2017","journal-title":"Osteoporos Int."},{"issue":"2","key":"2022081816085345700_CIT0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet."},{"issue":"9","key":"2022081816085345700_CIT0011","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta: a new form of brittle bone disease","volume":"15","author":"Glorieux","year":"2000","journal-title":"J Bone Miner Res."},{"issue":"10028","key":"2022081816085345700_CIT0012","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet."},{"issue":"10","key":"2022081816085345700_CIT0013","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00198-017-4143-8","article-title":"Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing","volume":"28","author":"Liu","year":"2017","journal-title":"Osteoporos Int."},{"issue":"7","key":"2022081816085345700_CIT0014","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate drug holiday and fracture risk: a population-based cohort study","volume":"33","author":"Adams","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2022081816085345700_CIT0015","doi-asserted-by":"crossref","first-page":"e82098","DOI":"10.1371\/journal.pone.0082098","article-title":"Bone mineral density of the spine in 11,898 Chinese infants and young children: a cross-sectional study","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One."},{"issue":"7","key":"2022081816085345700_CIT0016","first-page":"487","article-title":"Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years","volume":"47","author":"Li","year":"2009","journal-title":"Zhonghua Er Ke Za Zhi."},{"issue":"4","key":"2022081816085345700_CIT0017","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bone.2010.12.013","article-title":"Normative data and percentile curves for Dual Energy X-ray Absorptiometry in healthy Indian girls and boys aged 5-17 years","volume":"48","author":"Khadilkar","year":"2011","journal-title":"Bone."},{"issue":"9418","key":"2022081816085345700_CIT0018","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet."},{"issue":"12","key":"2022081816085345700_CIT0019","doi-asserted-by":"crossref","first-page":"e1525","DOI":"10.1002\/mgg3.1525","article-title":"A novel mutation in PLS3 causes extremely rare X-linked osteogenesis imperfecta","volume":"8","author":"Hu","year":"2020","journal-title":"Mol Genet Genomic Med."},{"key":"2022081816085345700_CIT0020","article-title":"Supplementary materials for: Relationship of pathogenic mutations and responses to zoledronic acid in a cohort of osteogenesis imperfecta children","author":"Sun","journal-title":"figshare"},{"issue":"9","key":"2022081816085345700_CIT0021","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc."},{"key":"2022081816085345700_CIT0022","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers."},{"issue":"5","key":"2022081816085345700_CIT0023","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2022081816085345700_CIT0024","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jbmr.2835","article-title":"Bone material properties in osteogenesis imperfecta","volume":"31","author":"Bishop","year":"2016","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2022081816085345700_CIT0025","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"2022081816085345700_CIT0026","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2022081816085345700_CIT0027","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/jbmr.3647","article-title":"Osteogenesis imperfecta: a need to understand divergent treatment outcomes in a disorder rich in heterogeneity","volume":"34","author":"Km","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2022081816085345700_CIT0028","first-page":"588","article-title":"Genotypic and phenotypic characterization of Chinese patients with osteogenesis imperfecta","volume":"40","author":"Li","year":"2019","journal-title":"Hum Mutat."},{"issue":"6","key":"2022081816085345700_CIT0029","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/jbmr.2172","article-title":"How tough is brittle bone? Investigating osteogenesis imperfecta in mouse bone","volume":"29","author":"Carriero","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2022081816085345700_CIT0030","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/jbmr.3421","article-title":"Low dose of bisphosphonate enhances sclerostin antibody-induced trabecular bone mass gains in Brtl\/+ osteogenesis imperfecta mouse model","volume":"33","author":"Olvera","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2022081816085345700_CIT0031","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2022081816085345700_CIT0032","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bone.2003.11.019","article-title":"Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy","volume":"34","author":"Arikoski","year":"2004","journal-title":"Bone."},{"issue":"8","key":"2022081816085345700_CIT0033","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","article-title":"Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta","volume":"23","author":"Lindahl","year":"2015","journal-title":"Eur J Hum Genet."},{"key":"2022081816085345700_CIT0034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bone.2016.02.018","article-title":"Scoliosis in osteogenesis imperfecta caused by COL1A1\/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment","volume":"86","author":"Sato","year":"2016","journal-title":"Bone."},{"issue":"1","key":"2022081816085345700_CIT0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00198-015-3216-9","article-title":"Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study","volume":"27","author":"Otaify","year":"2016","journal-title":"Osteoporos Int."},{"issue":"3","key":"2022081816085345700_CIT0036","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00774-017-0840-9","article-title":"Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta","volume":"36","author":"Kanno","year":"2018","journal-title":"J Bone Miner Metab."},{"key":"2022081816085345700_CIT0037","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fendo.2019.00924","article-title":"Management of osteogenesis imperfecta","volume":"10","author":"Ralston","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"5","key":"2022081816085345700_CIT0038","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00223-019-00655-5","article-title":"Sclerostin-antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim\/oim mice","volume":"106","author":"Cardinal","year":"2020","journal-title":"Calcif Tissue Int."},{"issue":"9","key":"2022081816085345700_CIT0039","doi-asserted-by":"crossref","first-page":"e10530","DOI":"10.1002\/jbm4.10530","article-title":"Inhibition of TGF-beta increases bone volume and strength in a mouse model of osteogenesis imperfecta","volume":"5","author":"Greene","year":"2021","journal-title":"JBMR Plus."},{"issue":"12","key":"2022081816085345700_CIT0040","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/jcm7120479","article-title":"Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis-case series","volume":"7","author":"Kobayashi","year":"2018","journal-title":"J Clin Med."},{"issue":"1","key":"2022081816085345700_CIT0041","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","article-title":"Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect","volume":"17","author":"Glorieux","year":"2002","journal-title":"J Bone Miner Res."},{"key":"2022081816085345700_CIT0042","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J Rare Dis."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac366\/45030576\/dgac366.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/9\/2571\/45476747\/dgac366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/9\/2571\/45476747\/dgac366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T12:15:18Z","timestamp":1660824918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/9\/2571\/6612527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,6,21]]},"published-print":{"date-parts":[[2022,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac366","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,6,21]]}}}